Significant Revenue Growth
Total revenue for Q3 2025 was $54 million, representing a 54% increase from Q3 2024. Software revenue was $40.9 million, a growth of 28% year-over-year.
Drug Discovery Revenue Surge
Drug discovery revenue reached $13.5 million, a significant increase from $3.4 million in Q3 2024, reflecting successful execution across collaborations.
Operational Efficiency and Expense Management
R&D expenses decreased by 16% to $42.8 million, and overall operating expenses decreased by 14% compared to Q3 2024.
Strong Cash Position
The company remains well-capitalized with $401 million in cash and equivalents as of September 30, 2025.